Mechanism of Action
THR-18 is a short (18-mer) peptide, derived from Plasminogen Activator Inhibitor-1 (PAI-1). When co-administered with tPA, THR-18
has been shown in a variety of animal studies to improve significantly both tPA’s efficacy and safety profile.
binds to the modulatory docking site for PAI-1 on the tPA molecule, rather than the molecule’s catalytic site. This modifies the tPA
molecule by preventing chemical interaction, which trigger harmful side-effects, between tPA and some of its non-embolic targets, thus
making it possible for the drug to dissolve blood clots without causing bleeding in the brain.
In addition, animal models have established that THR-18 can attenuate neurotoxicity induced by tPA, which activates harmful excitatory pathways. It was also found that THR-18 prevents the deleterious opening of the blood brain barrier following tPA administration, which causes swelling of the brain and damage to the nerves.
THR-18 may also be used to treat traumatic head injuries, Peripheral Arterial and Venous Occlusion, an Acute Myocardial Infarction (AMI) – also known as a severe heart attack – and Pulmonary Embolism which is characterized by the blockage of blood supply to the lungs. |
